Compare SHAK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | GH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 13.3B |
| IPO Year | 2014 | 2018 |
| Metric | SHAK | GH |
|---|---|---|
| Price | $91.86 | $92.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 19 |
| Target Price | $115.65 | ★ $120.05 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | 6.74 |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,445,306,000.00 | $982,021,000.00 |
| Revenue This Year | $16.38 | $33.30 |
| Revenue Next Year | $14.92 | $28.19 |
| P/E Ratio | $84.94 | ★ N/A |
| Revenue Growth | 15.38 | ★ 32.88 |
| 52 Week Low | $74.46 | $36.36 |
| 52 Week High | $142.23 | $120.74 |
| Indicator | SHAK | GH |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 52.20 |
| Support Level | $85.64 | $89.32 |
| Resistance Level | $97.09 | $103.16 |
| Average True Range (ATR) | 3.97 | 4.50 |
| MACD | 0.60 | 1.30 |
| Stochastic Oscillator | 79.99 | 72.47 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.